Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: New insights

European Journal of Haematology

Volumn 87, Issue 1, 2011, Pages 73-79

  Musallam, Khaled M ^a   Khoury, Brigitte ^a   Abi Habib, Rudy ^a   Bazzi, Lama ^a   Succar, Julien ^a   Halawi, Racha ^a   Hankir, Ahmed ^a   Koussa, Suzanne ^b   Taher, Ali T ^a,b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Chronic disease; Clinical complications; Health related quality of life; Quality of life; Thalassaemia intermedia; Thalassaemia major

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGE; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENDER; HEALTH STATUS; HEART FAILURE; HEMATOPOIESIS; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; LEBANON; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL HEALTH; OSTEOPOROSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; SHORT FORM 36; SOCIAL STATUS; STATISTICAL ANALYSIS; THALASSEMIA MAJOR; THROMBOSIS;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LEBANON; MALE; MIDDLE AGED; QUALITY OF LIFE; SOCIAL CLASS; YOUNG ADULT;

EID: 79959520305     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01623.x     Document Type: Article

References (43)

1. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of Hemoglobin: Genetics Pathophysiology, and Clinical Management, 2nd edn. Cambridge: Cambridge University Press, 2009.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93.
3. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.
4. Telfer P, Constantinidou G, Andreou P, Christou S, Modell B, Angastiniotis M. Quality of life in thalassemia. Ann N Y Acad Sci 2005;1054:273-82.
5. Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin 2009;33(Suppl. 1):S145-59.
6. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010;150:486-9.
7. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-92.
8. Mohamed N, Jackson N. Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion. Blood Rev 1998;12:163-70.
9. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol 2011. doi:. Epub ahead of print.
10. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995;80:58-68.
11. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40S-7S.
12. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J 1992;67:289-96.
13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
14. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002;8:457-69.
15. El-Hajj Fuleihan G, Baddoura R, Awada H, Arabi A, Okais J. First update of the Lebanese guidelines for osteoporosis assessment and treatment. J Clin Densitom 2008;11:383-96.
16. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, Kalinyak KA, Hudes M, Bhatia S, Vichinsky EP. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-82.
17. Sabbah I, Drouby N, Sabbah S, Retel-Rude N, Mercier M. Quality of life in rural and urban populations in Lebanon using SF-36 health survey. Health Qual Life Outcomes 2003;1:30.
18. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996.
19. Thavorncharoensap M, Torcharus K, Nuchprayoon I, Riewpaiboon A, Indaratna K, Ubol BO. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord 2010;10:1.
20. Clarke SA, Skinner R, Guest J, Darbyshire P, Cooper J, Shah F, Roberts I, Eiser C. Health-related quality of life and financial impact of caring for a child with Thalassaemia Major in the UK. Child Care Health Dev 2010;36:118-22.
21. Shaligram D, Girimaji SC, Chaturvedi SK. Psychological problems and quality of life in children with thalassemia. Indian J Pediatr 2007;74:727-30.
22. Ismail A, Campbell MJ, Ibrahim HM, Jones GL. Health Related Quality of Life in Malaysian children with thalassaemia. Health Qual Life Outcomes 2006;4:39.
23. Mikelli A, Tsiantis J. Brief report: depressive symptoms and quality of life in adolescents with b-thalassaemia. J Adolesc 2004;27:213-6.
24. Dahlui M, Hishamshah MI, Rahman AJ, Aljunid SM. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. Singapore Med J 2009;50:794-9.
25. Jafari H, Lahsaeizadeh S, Jafari P, Karimi M. Quality of life in thalassemia major: reliability and validity of the Persian version of the SF-36 questionnaire. J Postgrad Med 2008;54:273-5.
26. Messina G, Colombo E, Cassinerio E, Ferri F, Curti R, Altamura C, Cappellini MD. Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med 2008;3:339-43.
27. Scalone L, Mantovani LG, Krol M, et al. Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin 2008;24:1905-17.
28. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol 2011;86:92-5.
29. Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics 2008;121:e1426-9.
30. Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, Singer T, Vichinsky EP. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci 2005;1054:457-61.
31. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-29.
32. Payne KA, Desrosiers MP, Caro JJ, Baladi JF, Lordan N, Proskorovsky I, Ishak K, Rofail D. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007;47:1820-9.
33. Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: results from the ESCALATOR Trial. Acta Haematol 2010;123:220-5.
34. Zahed L, Mourad FH, Alameddine R, Aoun S, Koussa S, Taher A. Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia (Budap) 2002;31:333-9.
35. Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W. Health-related quality of life in children with sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer 2010;55:485-94.
36. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Prevalence of thromboembolic events among 8, 860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-91.
37. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 2007;47:792-800.
38. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M, Cesaretti C, Cappellini MD. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010;8:2152-8.
39. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010;8:54-9.
40. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009;147:634-40.
41. Di Palma A, Vullo C, Zani B, Facchini A. Psychosocial integration of adolescents and young adults with thalassemia major. Ann N Y Acad Sci 1998;850:355-60.
42. McPherson M, Thaniel L, Minniti CP. Transition of patients with sickle cell disease from pediatric to adult care: assessing patient readiness. Pediatr Blood Cancer 2009;52:838-41.
43. Levine L, Levine M. Health care transition in thalassemia: pediatric to adult-oriented care. Ann NY Acad Sci 2010;1202:244-7.